PWZ-029
Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID |
|
| ChemSpider |
|
| ChEMBL |
|
| Chemical and physical data | |
| Formula | C14H14ClN3O2 |
| Molar mass | 291.74 g·mol−1 |
| 3D model (JSmol) |
|
| |
InChI
| |
 N Y (what is this?) (verify) | |
PWZ-029 is a benzodiazepine derivative drug with nootropic effects developed by WiSys,[1] It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABAA receptor, acting as a partial inverse agonist at the α5 subtype and a weak partial agonist at the α3 subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.[2]
See also
- GABAA receptor negative allosteric modulator
- GABAA receptor § Ligands
- GL-II-73
References
- ^ US Patent application US2006/258643 A1
- ^ Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM (May 2008). "PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats". Brain Research. 1208: 150–9. doi:10.1016/j.brainres.2008.02.020. PMC 2577822. PMID 18394590.
- v
- t
- e
GABA receptor modulators
| GABABTooltip γ-Aminobutyric acid B receptor |
|
|---|
- See also
- Receptor/signaling modulators
- GABAA receptor positive modulators
- GABA metabolism/transport modulators
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
